Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic
leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main
purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab.
Participation could last up to four years, and possibly longer, if the disease does not
progress.